Evidence map›Paper›PMID 19716939›Full record

GuidelineGynecologic oncology2009

American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Sarah Temin

Erratum issuedAbstract readPractice Guideline
In one paragraph

Guideline in Gynecologic oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Medical treatment of uterine leiomyoma.Reproductive sciences (Thousand Oaks, Calif.) · 2012
    Review
  5. Innovative oral treatments of uterine leiomyoma.Obstetrics and gynecology international · 2012
    Article
  6. Article
  7. Vaccine prevention of cancer: can endogenous antigens be targeted?Cancer prevention research (Philadelphia, Pa.) · 2010
    Review
  8. Article
  9. Osteoporosis care in the United States after declines in reimbursements for DXA.Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
    Article
4 · The record

Corrections and comments

  • Erratum issued
    Visvanathan, Kala [added]; Lippman, Scott M [added]; Hurley, Patricia [added]
5 · Who and what money

Authors and funding

1 author.

Sarah TeminAmerican Society of Clinical Oncology, Cancer Policy and Clinical Affairs Department, 2318 Mill Road, Suite 800, Alexandria, VA 22314, USA.

Funding

K07 Preventive Oncology Academic AwardK07CA111948 · NCI · JOHNS HOPKINS UNIVERSITY · PI VISVANATHAN, KALA · 2005 to 2009
$701k
NCI NIH HHS K07 CA111948
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsFemaleFenretinideHumansRaloxifene HydrochlorideTamoxifenAromatase InhibitorsFenretinideRaloxifene HydrochlorideTamoxifen

Identifiers

PMID19716939
PMCPMC4119170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.